CISCO SYSTEMS, INC. et al. v. InfoExpress Inc.

IPR2024-00540

The USPTO denied Cisco and Fortinet's request for Director review of a prior institution denial in IPR2024-00540, leaving the original decision unchanged.

Jurisdiction
US PTAB
Case Number
IPR2024-00540
Decision Date
3 August 2024
Filing Date
3 August 2024

Detailed Summary

In IPR2024-00540 concerning U.S. Patent 8,347,350, Cisco Systems and Fortinet petitioned for Director review of the USPTO's earlier decision to deny institution of an inter partes review against InfoExpress. Director Katherine K. Vidal recused herself, and Deputy Under Secretary Derrick Brent evaluated the request. The Director ultimately denied the review, affirming the original institution denial and concluding the petitioners' attempt to revive the IPR.

Practitioner Note

This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in CISCO SYSTEMS, INC. et al. vs InfoExpress Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.

Related Cases

patentIPR2024-01237

Arista Networks, Inc.vsOrckit Corporation

Arista Networks has filed a petition challenging U.S. Patent No. 7,545,740 held by Orckit Corporation, asserting obviousness under 35 U.S.C. § 103. The petitioner argues that the claimed bi-directional link aggregation and hash-based selection mechanisms were already known in prior art references like Bruckman, Basso, and Holdsworth. This challenge targets core networking technology used for load balancing.

patentIPR2024-00703

BTL Industries, Inc.vsInMode Ltd.

ThermiGen settled its patent infringement lawsuit with Viveve Medical, securing a non‑exclusive license and agreeing to pay royalties. The settlement resolves the 2016 litigation and allows Thermi to continue developing its temperature‑controlled RF platforms for women's intimate health.

patentIPR2024-01067

smaXtec Inc. et al.vsST Reproductive Technologies, LLC

The PTAB found several claims of the '644 patent unpatentable based on anticipation (35 U.S.C. § 102) and obviousness (35 U.S.C. § 103). The Board concluded that prior art references, specifically Harvey and Riskey, disclosed all elements of key claims related to animal monitoring bolus sensors.

patentIPR2025-00155

Trove Brands, LLCvsCamelBak Products, LLC

Trove Brands has filed an IPR petition seeking cancellation of 16 claims of CamelBak’s 11,684,187 patent covering drink containers with removable caps. The petition relies on prior art from Kiyota, Choi, Park, and Ribarits to argue obviousness and asserts a means‑plus‑function construction for the “user release mechanism.”

patentIPR2025-00068

CrowdStrike, Inc. et al.vsGoSecure, Inc.

GoSecure seeks Director Review to vacate the institution of two IPRs filed by CrowdStrike that challenge all 21 claims of U.S. Patent 9,954,872. The patent owner alleges the Board abused discretion by allowing duplicate petitions, misapplying claim ambiguity, and incorrectly construing “computer system.”

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call